ClinicalTrials.gg
Not yet recruitingNCT07245550Updated Nov 24, 2025

Thyroid and Adrenal Disorders in ICU

An observational study in Septic Shock, sponsored by Assiut University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Assiut University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Shock, Septic by Assiut University — 11 open to participants now, 11 under way, none of them phase 3. Shock, Septic · Assiut University.

Planned enrollment
Largest of 14
200 · median 87
Started
2025
with 2 others
Observational
14 of 16
10 open now
Primary completion
2026-12
later than 3 of 10 live
Registered
9th of 16
by date

Among the 16 studies in Shock, Septic by Assiut University, this one has the largest planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2025, is one of 14 observational ones, reaches primary completion later than 3 of the 10 other live ones, and was the 9th registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

11 of the 16 studies in Shock, Septic by Assiut University are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Shock, Septic by Assiut University, or all of them as a file.
02

Study summary

A dysregulated host response to infection results in organ failure and sepsis, a potentially fatal illness. Sepsis killed about 11 million people worldwide in 2017 and had a death rate close to 20 %

Read the detailed description

Sepsis syndromes span a clinical continuum with variable prognoses. Septic shock, the most severe complication of sepsis, carries high mortality. In response to an inciting agent, pro-inflammatory and anti-inflammatory arms of the immune system are activated in concert with the activation of monocytes, macrophages, and neutrophils that interact with the endothelium through pathogen recognition receptors to elaborate cytokines, proteases, kinins, reactive oxygen species, and nitric oxide .Sepsis syndromes caused by multidrug-resistant bacterial strains (methicillin-resistant Staphylococcus, vancomycin-resistant enterococci are on the rise with a current incidence of up to 25%; viruses and parasites cause far fewer cases and are identified in 2% to 4% of cases . It is a well-known fact that the thyroid gland plays an important role in regulating metabolism, growth, and development by secretion of hormones such as thyroxine (T4) and triiodothyronine (T3). In critical illness, changes occur in the hypothalamic-pituitary-thyroid (HPT) axis which leads to euthyroid sick syndrome or non-thyroidal illness syndrome (NTIS). This condition is characterized by decreased T3 levels, normal to low levels of T4, and normal to decreased thyroid-stimulating hormone (TSH) levels despite the absence of intrinsic thyroid disease in patients. The pathophysiology of NTIS involves alterations in thyroid hormone production, peripheral conversion of T4 to T3, and increased degradation of thyroid hormones. During critical illness, cytokines and inflammatory mediators such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) play a significant role in these hormonal changes. Reduced activity of deiodinases, enzymes responsible for the conversion of T4 to T3, further contributes to decreased T3 levels. Critical illness is associated with increased systemic cortisol availability, a vital part of the stress response. Stress can cause life-threatening adrenal crisis when a disease of the hypothalamic-pituitary-adrenal (HPA) axis is present and not adequately treated with stress doses of hydrocortisone. Hence understanding these changes is vital to improve prognosis in patients under intensive care. For instance, in the absence of adrenal insufficiency, stress doses of hydrocortisone can be used to reduce the high vasopressor need in patients suffering from septic shock .In response to stress, adrenal gland generates high levels of glucocorticoid (GC). We call this induced GC (IGC). Unfortunately, 25-60% of septic patients experience relative adrenal insufficiency (RAI). RAI is defined by impaired IGC production in response to stress, which is diagnosed by a delta total cortisol of \< 9 μg/dL post-ACTH stimulation. Thus, understanding the endocrine changes and correction of these hormone levels as early as possible may reduce the hospitalization duration, thereby improving the prognosis of the patients. However, there is a lacuna in the literature regarding the level of these hormones at various timelines in critically ill patients classified according to the APACHE II classification in India. With the available data, we aimed to determine the thyroid and cortisol changes in acute severely ill patients and to assess their relationship with the severity of illness.

03

Conditions studied

  • Septic Shock

Browse trials for

Keywords

  • septic shock
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with septic shock admitted at intensive care unit and their age is above 18 years old

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All Patients who match the diagnostic criteria for sepsis/septic shock as stated
  • admitted in ICU

Exclusion criteria

Exclusion Criteria:

  1. Patients refuse to be enrolled in the study
  2. Patients with previous endocrinal disorders.
  3. Patients receiving or thyroid hormonal therapy.
  4. Pregnancy or lactation.
  5. Previous endocrinal gland surgery.
  6. Individuals with pacing rhythms, bundle branch blocks (QRS interval >120 ms),
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with septic shock in the ICU

    Blood sampling for thyroid and adrenal hormones

    Diagnostic Test: Blood sampling

Interventions

  • Diagnostic testBlood sampling

    Blood sampling for the hormones

06

What researchers measure

Primary outcomes

  1. serum Thyroid and adrenal hormones levels

    measurement of thyroid and adrenal hormones (TSH-FT3-FT4 - cortisol level ) will be measured by ELLISA technique in septic shock patients at ICU.

    Time frame: 24 hours

07

Study locations

1 site
  • Radwa mahmoud
    Asyut, Egypt
    • Assuit U Hospital · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Dec 2026, 12 months later.

Of 189 non-industry observational studies under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 47. This study's planned 12 months is below that.

Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2025
First posted
Nov 24, 2025
StartEst.
Dec 1, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07245550
Lead sponsor
Assiut University
Responsible party
Radwa mahmoud elsayed (principal investigator, Assiut University) — Principal investigator
First posted
Nov 24, 2025
Start date
Dec 1, 2025 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Nov 24, 2025

Study contacts

Radwa M Elsayed, MB
Contact
Radwaamahmoud11@gmail.com
01001673731 ext. 01001673731
Mohamed F Adawy, MB
Contact
DR-m.faisal85m@aun.edu.eg
01001244126 ext. 01001244126
Radwa m elsayed, MB
principal investigator · assuit university hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion